Celon Pharma S.A. (WSE:CLN) is planning to raise PLN 216 million (EUR 47.51 million /USD 56.43 million) via a public offering of 6 million shares priced at PLN 36 each. The funds will be used to fund the development and commercialisation of the company's most advanced clinical development projects, such as Falkieri-Esketamine for bipolar drug-resistant depression, CPL116-jak/rock inhibitor for autoimmune diseases and CPL36-PDE10A inhibitor for schizophrenia and Polehydrop Dyskinesia.